{
  "id": 1464194,
  "title": "Vivos Therapeutics stock falls 6% on second quarter revenue miss",
  "url": "https://urgent.news/2026/08/17/vivos-therapeutics-stock-falls-6-on-second-quarter-revenue-miss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T10:22:00.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/vivos-therapeutics-stock-falls-6-on-second-quarter-revenue-miss-93CH-4862533"
  },
  "original_language": "en",
  "account": "Vivos Therapeutics Inc. (VVOS) reported disappointing second quarter results on Monday, missing revenue projections and causing a 6.5% drop in its stock price during pre-market trading. The medical device company generated $5.15 million in revenue for the quarter, falling short of the analyst consensus of $5.57 million. Despite this, Vivos posted an adjusted loss per share of -$0.31, surpassing the estimated -$0.37. The surge in revenue, up 35% year-over-year, was primarily attributed to increased service revenue from sleep testing and treatment services in their Nevada operations. For the full six months ending June 30, 2026, revenue reached $10.3 million, a 51% increase from $6.8 million in the same period last year. Gross margin improved to 57% in the second quarter, up from 55% a year earlier. However, operating loss remained stagnant at $4.9 million compared to the same period in 2025. With $1.8 million in cash and cash equivalents as of June 30, 2026, the company faced a $3.8 million deficit in stockholders' equity, up from a $1.5 million deficit at year-end 2025. Vivos did not disclose financial guidance for upcoming quarters.",
  "summary": null,
  "key_points": [
    "Vivos Therapeutics missed revenue projections by $0.42 million",
    "Sleep testing and treatment services drove 35% year-over-year revenue growth",
    "Company ended June 30 with $3.8 million equity deficit"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}